Once-daily treatment with ciclesonide is effective and well-tolerated in children with persistent asthma

Shapiro, G.G.; Bensch, G.; Lanier, Robert Q.; Sher, Lawrence; Lloyd, Mark; Kundu, Sudeep; Fish, J.; Williams, John W; Banerji, Donald

doi:10.1016/j.jaci.2004.12.037

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the current study are consistent with those of previous studies that examined the effect of ciclesonide treatment in children with asthma (19, 25). In this study, similar efficacy in the treatment of asthma was achieved when ciclesonide was administered at half the daily dose of budesonide.…”

Section: Discussionsupporting

confidence: 91%

Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma

Berg

Engelstätter²,

Minić

et al. 2007

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk.

show abstract

Section: Discussionsupporting

confidence: 91%

Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma

Berg

Engelstätter²,

Minić

et al. 2007

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

Safety of inhaled corticosteroids: Room for improvement

Rossi¹,

Cerasoli²,

Cazzola

2007

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Phenotypes and Endotypes of Bronchial Asthma: From Pathogenesis and Clinical Features to Therapy

Курбачева

Pavlova

2013

Russian Journal of Allergy

View full text Add to dashboard Cite

Questions of bronchial asthma heterogeneity, approaches to allocation of various phenotypes on the basis of clinical signs, biological and genetic markers and endotypes taking into account an etiology and pathophysiology of the disease are considered in the article. Allocation of phenotypes / endotypes promote the best understanding of essence of a disease and it is expedient for development of an individual approach to therapy as some options of a current OH can differ the resistant answer to standard treatment.

show abstract

Once-daily treatment with ciclesonide is effective and well-tolerated in children with persistent asthma

Cited by 3 publications

References 0 publications

Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma

Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma

Safety of inhaled corticosteroids: Room for improvement

Phenotypes and Endotypes of Bronchial Asthma: From Pathogenesis and Clinical Features to Therapy

Contact Info

Product

Resources

About